Search Bar & Filters
Found 48 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for extensive-stage small cell lung cancer ES-SCLC, a type of lung cancer that has spread widely within the lungs or to other parts of the body. This study evaluates the combination of two investigational drugs, gocatamig and ifinatamab deruxtecan I-DXd, alongside standard chemotherapy and immunotherapy treatments. The research aims to understand the safety and tolerability of these combined therapies and whether they can reduce or eliminate cancer in participants. Participants in the trial may receive different treatment regimens depending on their prior therapy history. Some will receive gocatamig and I-DXd together in maintenance after standard chemotherapy and immunotherapy, while others will receive these drugs during both induction and maintenance phases. Additional groups will receive combinations including gocatamig, I-DXd, atezolizumab, carboplatin, and etoposide in varying sequences. Treatments are delivered intravenously, and participants continue until disease progression or other criteria require stopping. During the study, participants will have regular assessments including imaging to measure tumor response, safety monitoring for adverse events, and laboratory tests to understand drug levels and immune reactions. Researchers will track side effects, dose-limiting toxicities, and treatment discontinuations over a period of up to about 58 months. The main outcomes include tumor response and safety, with ongoing evaluation of disease control, survival, and drug exposure throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.
Actively Recruiting
Researchers are evaluating the safety and potential benefits of the investigational drug BNT329 in adults with advanced solid tumors known to express the tumor marker CA19-9. This multi-part phase IIIa trial aims to find the best dose of BNT329 by monitoring side effects and measuring how well participants respond to treatment, including how long their tumors remain stable. The study also investigates how BNT329 moves through and affects the body. The study includes up to four parts Parts A and B focus on dose escalation to assess safety and tolerability in participants with various advanced cancers expressing CA19-9, such as pancreatic, bile duct, bladder, colorectal, gastric, endometrial, and ovarian cancers. Part C may be opened if safety or efficacy concerns arise and involves pre-dosing with a CA19-9 targeting monoclonal antibody. Part D is a dose optimization and proof-of-concept phase enrolling participants with pancreatic cancer who have progressed after prior therapies. Treatments involve intravenous infusions of BNT329 administered every 2 or 3 weeks, with some participants randomized to different dose levels. Participants will undergo a screening period followed by up to 2 years of treatment, including an end-of-treatment visit and two safety follow-up visits. After treatment, participants will enter a survival follow-up phase lasting until death, withdrawal, or study end. Throughout the study, researchers will assess side effects, tumor response, drug levels, and survival outcomes using clinical evaluations and laboratory tests to monitor safety and effectiveness.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a mentalization-based prevention program aimed at improving well-being and mental health in children aged 8 to 10 years and their families across four European countries Germany, Lithuania, Spain, and Switzerland. The study is designed as a partially randomized controlled trial and investigates how multi-level interventions involving children, parents, and teachers can promote mental health, reduce stigma, enhance help-seeking behavior, and improve classroom climate and parenting skills. The program includes a universal prevention workshop delivered at schools for all children, focusing on mental health awareness and peer support skills. Parents receive one of two different intervention trainings or a parenting guidebook one group attends 10 weekly sessions of the Lighthouse Program targeting secure attachment and reflective parenting behaviors, and another group participates in 6 bi-weekly Mentalization Based Skills Training sessions focusing on attentional control and emotion regulation. An active control group receives a parenting guidebook, while a passive control group participates in follow-up assessments without intervention. Participants will be involved in data collection at multiple time points baseline, post-intervention at 3 months, and follow-ups at 6 and 12 months. Assessments include questionnaires measuring childrens and parents well-being and mental health, parental efficacy and stress, classroom climate, teaching efficacy, and mental health stigma. Focus groups after the post-assessment will gather feedback on implementation and satisfaction. The study aims to follow 5,000 children, their parents, and teachers over a year to evaluate long-term program effects.
Actively Recruiting
Researchers are evaluating PLN-101095 combined with pembrolizumab in adults with advanced or metastatic solid tumors that have progressed despite prior pembrolizumab treatment. This Phase 1a1b open-label study aims to assess the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early signs of antitumor activity of this combination in patients with documented resistance to immune checkpoint inhibitors. The study includes two parts Part 1 involves consecutive dose-escalation cohorts of PLN-101095 at varying doses 250 mg to 2000 mg, administered twice or three times daily combined with pembrolizumab given intravenously every three weeks. Part 2 expands dosing cohorts to evaluate the combination and PLN-101095 monotherapy in specific tumor types, including non-small cell lung cancer, clear cell renal cell carcinoma, and tumor mutational burden-high solid tumors. Participants undergo treatment cycles with regular safety and tumor assessments, including monitoring of side effects and drug levels. Researchers will measure outcomes such as safety and tolerability from first dose through 16 weeks post-treatment, as well as antitumor activity until disease progression or death. The study spans up to several years, with ongoing evaluations to understand the treatments effects and duration of response.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and antitumor activity of GEN1119 in participants with certain types of solid tumors in this first-in-human, open-label Phase 1 trial. The study aims to find the best dose of GEN1119 and assess how well it works in treating these cancers. This trial is sponsored by Genmab and involves multiple parts to test different doses and refine the treatment approach. Participants will receive GEN1119 at various dose levels depending on the trial phase. The trial includes three parts initial dose escalation to determine safety and optimal doses, dose refinement to further define the best dose, and an expansion phase where participants receive GEN1119 at the recommended dose. All participants receive the active drug, with no placebo group. Administration schedules and dose levels vary as the study progresses. The trial lasts about 18 months for each participant, including up to 21 days of screening, around 5 months of treatment, and approximately 12.5 months of follow-up. Participants will visit the study site frequently during the first 6 weeks of treatment, then less often afterward. During visits, tests such as blood draws, heart activity monitoring, and CT scans will be performed to assess safety and treatment effects. Researchers will monitor dose-limiting toxicities, adverse events, and tumor response rates throughout the trial.
Actively Recruiting
Researchers are evaluating how well people with small cell lung cancer SCLC tolerate different doses of alisertib when combined with paclitaxel. This Phase 2 open-label trial focuses on patients who have had prior treatments including platinum-based chemotherapy and immunotherapy. The study aims to understand the side effects participants experience based on standardized criteria during treatment cycles. Participants take alisertib orally twice a day from Day 1 through Day 7 in each 21-day cycle, with doses starting at 30 mg twice daily and increasing by 10 mg in successive groups of about ten participants. Paclitaxel is given intravenously on Days 1 and 8 of each cycle. After each cycle involving alisertib, participants receive a preventive injection called granulocyte-colony stimulating factor G-CSF to support the bodys defenses. Blood samples are collected on Days 1 and 7 of the first two cycles to monitor alisertib levels. Treatment continues until disease progression, unacceptable side effects, death, or withdrawal from the study. After stopping treatment, participants enter a long-term follow-up phase with contact every 8 weeks until death, study end, or withdrawal. Researchers assess side effects, response to treatment, disease control, progression-free survival, and overall survival over up to 24 months, carefully monitoring safety throughout the study.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide in adults with moderate-to-severe obstructive sleep apnea OSA who are also obese or overweight. The study uses a master protocol called YDAO that includes two separate studies YSA1 for participants who cannot or do not want to use Positive Airway Pressure PAP therapy, and YSA2 for those who have been on PAP therapy for at least three months and plan to continue it during the study. The goal is to understand how eloralintide affects body weight and sleep apnea severity. Participants will be randomly assigned to receive either eloralintide or a placebo, both given as weekly subcutaneous injections. The study lasts about 76 weeks and includes two groups based on PAP therapy use. During the study, participants will continue their current PAP therapy status according to their assigned group. The study is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the study, participants will undergo assessments at baseline and Week 64, including measuring changes in body weight, apnea-hypopnea index AHI, blood pressure, triglycerides, sleep-related impairment, and other health markers. Researchers will also monitor safety, medication use, and pharmacokinetics. Participants can expect regular visits for evaluations and monitoring over the study period to understand the effects of eloralintide on OSA and obesity-related health factors.
Actively Recruiting
Researchers are evaluating the drug BAY 3713372 to treat solid tumors that have a specific genetic deletion called MTAP deletion. This first-in-human study aims to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with these tumors. The study focuses on measuring side effects, toxicities, drug levels in the blood, and participants responses to treatment as well as how long their cancer remains stable. Participants will receive BAY 3713372 taken by mouth daily. The study has two parts a dose escalation phase where different groups receive increasing doses of the drug alone to find a safe and effective dose, followed by a dose expansion phase where more participants receive BAY 3713372 alone or combined with other treatments based on the dose found. Some groups focus on specific tumor types, including non-small cell lung cancer, pancreatic cancer, and glioblastoma. Participants will visit the study site at least twice before treatment starts and multiple times during treatment. After treatment ends, they will have follow-up visits every 9 weeks until their cancer worsens or they stop the study. Throughout the trial, health assessments include blood and urine tests, heart monitoring with electrocardiograms, scans like CT or MRI to check cancer status, and tumor sample collection. The research team will also contact participants every 3 months for up to 2 years after their last dose to monitor health and safety.
Actively Recruiting
Researchers are evaluating the safety and tolerability of valemetostat combined with darolutamide in adult males with Metastatic Castration Resistant Prostate Cancer mCRPC. This phase 1 trial aims to understand how these treatments work together in participants who have evidence of disease progression and metastatic spread, while continuing androgen deprivation therapy. The study is sponsored by Daiichi Sankyo and focuses on participants who have prior therapy with androgen receptor pathway inhibitors. Participants will receive valemetostat at escalating doses alongside a standard dose of darolutamide. The trial includes a dose escalation part where dosing is carefully increased, followed by a dose expansion part with two or more dose levels of valemetostat combined with darolutamide. Treatment cycles last 28 days, with valemetostat dosing monitored closely during the initial cycle and repeated in subsequent cycles. Participants will undergo assessments from screening through up to approximately 5 years, including monitoring for dose-limiting toxicities, treatment-emergent adverse events, and prostate-specific antigen PSA responses. Additional evaluations include radiographic progression, overall survival, and time to symptomatic skeletal events. Blood samples will be collected to measure plasma concentrations of the study drugs. Safety and efficacy will be closely tracked throughout the study duration.
1-10 of 48
1